New Hepatitis C Combo Treatment Is Highly Effective in Clinical Trials
The combination of sofosbuvir (Sovaldi) and ravidasvir (an investigational NS5A inhibitor) is safe and effective for people with hepatitis C (HCV), including those with hard-to-treat hep, according to results of a clinical trial being conducted by the Drugs for Neglected Diseases Initiative, a non-profit research and development organization.
The trial involved 301 adults with chronic HCV infection. Those who did not have cirrhosis of the liver were treated with the ravidasvir/sofosbuvir combination for 12 weeks, and those with cirrhosis were treated for 24 weeks. According to research presented this week at the International Liver Conference in Paris, this drug combination had an overall cure rate of 97 percent.
Cure rates in hard-to-treat patients were 96 percent for those with liver cirrhosis and those exposed to prior hep C treatments, and 97 percent for patients living with HIV and those infected with genotype 3 hepatitis. The World Health Organization reports that more than 71 million people worldwide live with hepatitis C; the disease causes about 400,000 deaths each year. Highly effective treatments for hep C have existed for years, but currently, fewer than 3 million people are receiving medical treatment.